A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): A pilot study of nine Japanese patients with TSC of different disease severity

British Journal of Dermatology

Volumn 165, Issue 4, 2011, Pages 912-916

  Wataya Kaneda, M ^a   Tanaka, M ^a   Nakamura, A ^b   Matsumoto, S ^b   Katayama, I ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HEMANGIOFIBROMA; HUMAN; JAPANESE; LIQUID CHROMATOGRAPHY; MALE; MONOTHERAPY; OINTMENT; PAPULE; PILOT STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SKIN REDNESS; TREATMENT DURATION; TUBEROUS SCLEROSIS;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOFIBROMA; CHILD; DRUG COMBINATIONS; FACIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; PHARMACEUTICAL VEHICLES; PILOT PROJECTS; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 80053517662     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10471.x     Document Type: Article

References (14)

1. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805-8. (Pubitemid 27366729)
2. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305-15.
3. Inoki K, Li Y, Xu T, Guan KL,. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17: 1829-34. (Pubitemid 36944560)
4. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-8. (Pubitemid 43358069)
5. Herry I, Neukirch C, Debray MP, et al. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007; 18: 76-7. (Pubitemid 46091655)
6. Taille C, Debray MP, Crestani B,. Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med 2007; 146: 687-8. (Pubitemid 351650533)
7. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-51.
8. Hofbauer GF, Marcollo-Pini A, Corsenca A, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008; 159: 473-5. (Pubitemid 352009863)
9. Haemel AK, O'Brian AL, Teng JM,. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010; 146: 715-18.
10. Kaufman McNamara E, Curtis AR, Fleischer AB Jr,. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatolog Treat 2010 [Epub ahead of print]
11. Roach ES, Gomez MR, Northrup H,. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-8. (Pubitemid 29035481)
12. Brems H, Beert E, de Ravel T, Legius E,. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 2009; 10: 508-15.
13. Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 2009; 10: 1199-206.
14. Blumenthal GM, Dennis PA,. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008; 16: 1289-300.